Cameroon vs Guinea: Statin use vs. average non-HDL cholesterol levels
Cameroon
2.9
in 2018
Guinea
2.9
in 2018
Cameroon rank
154th
Guinea rank
154th
Statin use vs. average non-HDL cholesterol levels over time
- Cameroon
- Guinea
How they compare
Cameroon currently reports 2.9 against 2.9 in Guinea, a difference of 0.
The two have swapped places 5 times across 39 shared years of data; in 1980 it was Cameroon ahead.
Cameroon ranks 154th and Guinea ranks 154th of 191 countries.
Across the 4 decades both report, Cameroon averaged higher in 3 and Guinea in 1.
Head to head by decade
| Decade | Cameroon | Guinea | Difference | Ahead |
|---|---|---|---|---|
| 1980s | 2.58 | 2.5 | 0.08 | Cameroon |
| 1990s | 2.7 | 2.61 | 0.09 | Cameroon |
| 2000s | 2.76 | 2.72 | 0.04 | Cameroon |
| 2010s | 2.81 | 2.84 | 0.0333 | Guinea |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher statin use vs. average non-hdl cholesterol levels, Cameroon or Guinea?
- Cameroon, at 2.9 against 2.9 in Guinea as of 2018.
- What is the difference in statin use vs. average non-hdl cholesterol levels between Cameroon and Guinea?
- 0, with Cameroon ahead.
- How many years of comparable data are there for Cameroon and Guinea?
- 39 years are reported by both, from 1980 to 2018.
- How do Cameroon and Guinea rank globally for statin use vs. average non-hdl cholesterol levels?
- Cameroon ranks 154th and Guinea ranks 154th of 191 countries.
- Where does this data come from?
- World Health Organization – Global Health Observatory (2026) – with minor processing by Our World in Data, published as Statin use vs. average non-HDL cholesterol levels. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
The use of statins in the population. This is compared to average non-HDL cholesterol levels, in mmol/L. Statins are a type of drug that reduce non-HDL cholesterol levels, and are used to treat and prevent cardiovascular diseases in people at heightened risk. Their usage is measured in Defined Daily Doses, per 1,000 people.